BioMarin moved to expand Voxzogo after new clinical results supporting use in children with hypochondroplasia, a skeletal disorder related to achondroplasia. In a Phase 3 trial, participants treated with Voxzogo showed faster growth than placebo over one year, with increases in standing height and arm span—key functional outcomes for pediatric mobility and independence. The company’s push comes as competition for Voxzogo intensifies following recent achondroplasia approvals for rivals including Ascendis Pharma’s once-weekly injection and BridgeBio’s late-stage oral alternative. Analysts in the coverage suggested hypochondroplasia may still represent a sizable market, though questions remain about true prevalence and urgency to treat. —